You are here

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Letter to the editor
Correspondence on ‘Low-dose thrombolysis for submassive pulmonary embolism’ by Yilmaz and Uzun
  1. Ahmet Güner,
  2. Fatih Uzun,
  3. Ezgi Gültekin Güner,
  4. Cemalettin Akman,
  5. Mehmet Ertürk
  1. Department of Cardiology, University of Health Sciences, İstanbul Mehmet Akif Ersoy Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi, Istanbul, Turkey
  1. Correspondence to Dr Ahmet Güner, Department of Cardiology, İstanbul Mehmet Akif Ersoy Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi, 34303, Istanbul, Turkey; ahmetguner488{at}gmail.com

http://dx.doi.org/10.1136/jim-2022-002420

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor,

    We recently read with great interest the article by Yilmaz and Uzun,1 describing the efficacy and safety of low dose thrombolytic therapy (TT) in patients with acute submassive pulmonary embolism (PE). We would like to emphasize a few points in light of current evidence.

    PE is one of the most frequently reported thrombotic complications,2 and is more prevalent in critically ill patients with coronavirus disease 2019 (COVID-19). Thirty-day results have shown that patients with COVID-19 and PE received no significant benefit from empirically administered prophylactic anticoagulants at moderate doses against venous thrombosis or mortality.3 In submassive …

    View Full Text

    Footnotes

    • Contributors AG: Writing - manuscript preparation. FU: Writing - manuscript preparation. EGG: Manuscript preparation. CA: Literature research. ME: Writing, reviewing and editing.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles